Doug talks about the company’s mission to revolutionize mental healthcare, how Cybin is delivering powerful and effective therapies, and why being the first psychedelic-based company to list on the New York Stock Exchange was a natural fit. Cybin can be found on the NYSE under the ticker symbol $CYBN.
And in other psychedelic stock news, Origin Therapeutics launches to make equity investments in emerging psychedelics-related companies.
This week in psychedelic business news: It’s all about partnerships and acquisitions designed to advance psychedelic therapies for depression, suicidal ideation, pain, and more.
Cybin CEO says agreement “serves as a major step toward establishing a national distribution network for future psychedelic therapies.”
End of content
End of content
By signing up to the Psychedelic Spotlight newsletter you agree to receive electronic communications from Psychedelic Spotlight that may sometimes include advertisements or sponsored content.